The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke (CASTA)
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Anhui, China
- Anhui Shengli Hospital
-
Anshan, China
- Anshan hospital
-
Baotou, China
- Baotou Center Hospital
-
Baotou, China
- Third hospital, affiliated Neimenggu Medical University (Bao Gang hospital)
-
Beijing, China
- Sino-Japanese Friendship Hospital
-
Beijing, China
- Beijing PLA General Hospital
-
Beijing, China
- First hospital, affiliated Peking University
-
Beijing, China
- Friendship Hospital, affiliated Capital Medical University
-
Beijing, China
- Peking Anzhen Hospital
-
Canton, China
- Guangzhou 2nd People's Hospital
-
Changchun, China
- First hospital, affiliated Bethune Medical University
-
Changchun, China
- Second Hospital Affiliated Bethune Medical University
-
Changsha, China
- Xiangya Hospital, affiliated Hunan Medical University
-
Chengdu, China
- Chengdu 2nd People's Hospital
-
Chengdu, China
- First Hospital, affiliated Huaxi Medical University
-
Chengdu, China
- Sichuan Province People's Hospital
-
Chongqing, China
- Second Hospital, affiliated Chongqing Med. University
-
Dalian, China
- Dalian Center Hospital
-
Dalian, China
- Dalian third people Hospital
-
Dalian, China
- Second Hospital, affiliated Wenzhou Med. University
-
Fuzhou, China
- First hospital, affiliated Fujian Medical University
-
Fuzhou, China
- FuJian Shengli Hospital
-
Guandong, China
- First Hospital, affiliated Shantou Medical University
-
Guangzhou, China
- Guangzhou Red Cross Hospital
-
Hangzhou, China
- First Hospital, affiliated Medical college Zhejing University
-
Harbin, China
- The 4st Hospital affiliated Harbin Medical University
-
Kunming, China
- Second Hospital, affiliated Kunming Med. University
-
Mudanjiang, China
- Yinchuan People's Hospital
-
Nanjing, China
- Nanjing PLA General Hospital
-
Nanjing, China
- Zhongda hospital
-
Qingdao, China
- First Hospital, affiliated Qingdao Medical University
-
Shanghai, China
- Huashan Hospital, affiliated Fudan University
-
Shanghai, China
- Renji Hospital, affiliated Second Medical University
-
Shanghai, China
- Ruijin Hospital, affiliated Jiaotong University
-
Shanghai, China
- Shanghai 6th People's Hospital
-
Shanghai, China
- Xinhua hospital of Shanghai Jiaotong University School of Medicine
-
Shanghai, China
- Zhongshan Hospital, affiliated Fudan University
-
Shijiazhuang, China
- Hebei Province People's Hospital
-
Tianjin, China
- Tianjin First Medical Center
-
Tianjin, China
- Tianjin Union Medicine Centre
-
Wuhan, China
- Union Hospital, affiliated Huazhong science and technology University
-
Yinchuan, China
- First hospital, affiliated NingXia Mededical University
-
Zhengzhou, China
- First hospital, affiliated Henan Medical University
-
-
Heilongjiang
-
Mudanjiang, Heilongjiang, China
- Mudanjiang 1st people Hospital
-
Mudanjiang, Heilongjiang, China
- Mudanjiang 2nd people Hospital
-
-
-
-
-
Hong Kong, Hong Kong
- Chinese University of Hong Kong
-
-
-
-
-
Seoul, Korea, Republic of
- Asan Medical Center
-
Seoul, Korea, Republic of
- East-west neo medical center
-
Seoul, Korea, Republic of
- Kyung-Hee University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age between 18 and 85 years
- Focal neurological deficit
- Clinical diagnosis of acute hemispheric ischemic stroke
- CT or MRI results compatible with clinical diagnosis of acute hemispheric stroke
- NIH Stroke Scale Score between 6 and 22, both inclusive
- Functionally independent prior to stroke with a pre-stroke Rankin Score of 0 or 1
- Randomization and first treatment with the trial medication within 12h after stroke onset
- Informed consent given by the patient and/or the patient's legally acceptable representative
Exclusion Criteria:
- Evidence on CT/MRI of acute or chronic intracerebral hemorrhage, SAH, AVM, cerebral aneurysm, or neoplasm
- Signs of herniation, increased intracranial pressure or likely etiology other than brain ischemia at baseline CT scan
- Patients with a substantial decrease of consciousness or alertness at the time of randomization, defined as score of 2 or more one of the NIH Stroke Scale questions 1a.
- Neurological signs and symptoms that improve rapidly during screening and are likely to resolve completely within 24h
- Severe coexisting systemic disease that significantly limits life expectancy
- Systolic blood pressure over 220 mmHg or diastolic blood pressure over 120 mmHg on repeated measurement (interval of 30 min) prior to study entry
- Severe congestive heart failure or presentation with acute myocardial infarction at study entry
- Epilepsy or epileptic seizures at onset of stroke
- Pre-existing disorders or conditions that would impair interpretation of neurological assessment (eg. severe dementia, severe psychiatric illnesses, etc).
- Concomitant treatment with other neuroprotective or nootropic drugs (e.g. piracetam, citicoline, investigational neuroprotective substances)
- Patients which cannot tolerate or have contraindication to aspirin or Cerebrolysin treatment
- Concomitant treatment with substances that have a dilative effect on blood vessels like naftidrofuryl, cinnarizine, flunarizine or nimodipine
- Pregnancy and lactation period; for women with child-bearing potential a negative pregnancy test is required
- Participation in a clinical trial with an investigational drug in the past 4 weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Cerebrolysin
|
30 ml study drug will be given once daily by intravenous infusion for 10 consecutive days.
|
|
Placebo Comparator: 0.9% Saline Solution
|
30 ml will be given once daily by intravenous infusion for 10 consecutive days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Modified Rankin Scale
Time Frame: 90 days after start of treatment
|
90 days after start of treatment
|
|
Barthel Index
Time Frame: 90 days after start of treatment
|
90 days after start of treatment
|
|
NIH Stroke Scale
Time Frame: 90 days after start of treatment
|
90 days after start of treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
SF-12
Time Frame: 90 days after start of treatment
|
90 days after start of treatment
|
|
Overall mortality
Time Frame: Throughout the study
|
Throughout the study
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Philipp Novak, PhD, EVER Neuro Pharma
- Principal Investigator: Zhen Hong, MD, Huashan Hospital, affiliated Fudan University
Publications and helpful links
General Publications
- Hong Z, Moessler H, Bornstein N, Brainin M, Heiss WD; CASTA-Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of Cerebrolysin in patients with acute ischaemic stroke in Asia--CASTA. Int J Stroke. 2009 Oct;4(5):406-12. doi: 10.1111/j.1747-4949.2009.00340.x.
- Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z; Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012 Mar;43(3):630-6. doi: 10.1161/STROKEAHA.111.628537. Epub 2012 Jan 26.
- Bornstein NM, Guekht A, Vester J, Heiss WD, Gusev E, Homberg V, Rahlfs VW, Bajenaru O, Popescu BO, Muresanu D. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurol Sci. 2018 Apr;39(4):629-640. doi: 10.1007/s10072-017-3214-0. Epub 2017 Dec 16.
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Necrosis
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Brain Ischemia
- Infarction
- Brain Infarction
- Stroke
- Ischemic Stroke
- Ischemia
- Cerebral Infarction
- Physiological Effects of Drugs
- Neuroprotective Agents
- Protective Agents
- Nootropic Agents
- Cerebrolysin
Other Study ID Numbers
Other Study ID Numbers
- EBE-CN-050823
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.